Migraine drug ajovy put to the test for better sleep

NCT ID NCT04693533

Terminated Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether fremanezumab (Ajovy), an FDA-approved monthly injection for migraine prevention, could also improve sleep in people with migraines. Researchers planned to track 22 participants over 4 months, comparing their migraine days and sleep quality before and after treatment. The trial was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fremanezumab (Ajovy), a monthly anti-CGRP injection for migraine prevention
What this could lead to: If successful, this could show that fremanezumab improves both migraine and sleep quality, offering a dual benefit for patients.
What could go wrong: The trial was terminated early with only 22 participants, so results are limited. It is a small, single-group study without a placebo control, making it hard to draw firm conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder sleep disorder sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE DISORDERS SLEEP DISORDER

Contacts and locations

Locations

BIDMC Headaceh Clinic

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.